No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
GMAB Genmab
- 20.310
- +0.220+1.10%
Close Dec 20 16:00 ET
- 20.310
- 0.0000.00%
Post 16:03 ET
12.90BMarket Cap20.21P/E (TTM)
20.430High20.130Low1.83MVolume20.220Open20.090Pre Close37.12MTurnover0.29%Turnover Ratio22.15P/E (Static)635.24MShares32.88052wk High2.91P/B12.76BFloat Cap19.85052wk Low--Dividend TTM628.45MShs Float49.070Historical High--Div YieldTTM1.49%Amplitude16.240Historical Low20.290Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Bernstein Initiates Genmab(GMAB.US) With Hold Rating
Bernstein Upgrades Genmab to Market Perform, Lowers PT
Antibody Discovery Market Industry Forecast Report 2024-2035, Featuring Ablexis, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, MabSilico, Nona Biosciences, WuXi Biologics and More
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
TD Cowen Maintains Genmab(GMAB.US) With Hold Rating
TD Cowen Reaffirms Their Hold Rating on Genmab (GMAB)
Heat List
US
Overall
Symbol
Price
% Chg
No Data